Drug intelligence / Profile preview

AllerT3

Development stage: Preclinical
Lead developer: HAL Allergy
Modality: Peptides
Administration: Topical

Overview

AllerT3 is a synthetic peptide, specifically T3, derived from Bet v 1, the major allergen found in birch pollen. It is being developed by Anergis and is used in clinical trials to assess skin reactivity in individuals with birch pollen allergy through skin prick tests.

Other names: synthetic peptide T3

Beyond the preview

Go deeper on AllerT3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AllerT3.

Explore the full profile